#USA #Scottsdale #AI System #Oncology Trials #Imaging Endpoints

Imaging Endpoints Files Patent for Groundbreaking AI Review Charter System

In a significant advancement for clinical oncology trials, Imaging Endpoints (IE), a global leader in imaging technology and contract research organization (CRO) services, has announced the submission of a provisional patent for its innovative Imaging Review Charter (IRC) System, now branded as the AI-Driven AIRC System™. This groundbreaking initiative aims to enhance the customization and efficiency of IRCs in oncology studies, setting a new industry benchmark.

Imaging Endpoints has long been at the forefront of optimizing imaging capture and analysis in clinical studies, boasting a remarkable 95% success rate in market approvals across over 200 supported applications. The newly developed AIRC system is designed to tackle enduring challenges in imaging study design by effectively preparing data for intelligent, customized modifications. It aligns with the latest regulatory requirements established by the FDA, EMA, and other global authorities, ensuring that clinical trial designs comply with current standards.

Key Features of the AIRC System

Dynamic Adjustments

The AIRC system incorporates an adaptive module that compiles datasets from industry standards and published oncology criteria. This integration allows it to generate dynamic IRC documents, streamlining the study process.

Optimization Criteria

The system harnesses the most extensive dataset available in the field, employing advanced methods to identify specific criteria or alterations needed to optimize imaging capture and analysis for each study.

Improved Regulatory Compliance

By integrating diverse requirements, standards, and recent industry insights from regulatory agencies such as the FDA, the AIRC system enhances compliance with legal standards. It also provides clear descriptions of improvements made, boosting the efficiency of both the sponsor and regulatory body evaluation procedures.

Increased Efficiency

Utilizing artificial intelligence, the AIRC system compiles and integrates relevant data for analysis by Imaging Endpoints’ medical and scientific experts. This capability facilitates a quicker study setup while ensuring reliable results.

Doug Dean Burkett, the Executive Director and President of Imaging Endpoints, commented on this innovation: "For over 15 years, IE has led the imaging CRO services in oncology. The submission of this patent marks another milestone in our commitment to Connect Imaging to the Cure™. This AI-powered IRC system enhances both efficacy and efficiency in oncology studies, reinforcing our leadership position in the sector."

Imaging Endpoints focuses passionately on its vision to connect imaging with healing. The company holds an impeccable global inspection record, with an outstanding 95% success rate for market approvals worldwide. Known for its commitment to quality, innovation, rapid turnaround times, and operational excellence, IE has solidified its status as the largest oncology imaging CRO with eight offices across six countries including Scottsdale, Arizona, Cambridge, Massachusetts, London, UK, Leiden, Netherlands, Basel, Switzerland, Hyderabad, India, and Shanghai, China.

As a subsidiary of HonorHealth, one of the largest health systems in the United States, and Southwest Medical Imaging, Ltd. (SMIL/RadPartners), the largest private radiology group in the country, Imaging Endpoints continues its mission to drive improvement in clinical trials and patient outcomes globally.

For more information or to access a copy of Imaging Endpoints' latest white paper, Optimizing Imaging Response Criteria for Improved Outcomes in Oncology Clinical Trials, please visit their official website or reach out via email at [email protected] or contact number: +1 480-314-3070.